

Generation of anti-*Giardia* antibodies by bacteriophage antibody display

Victoria C. Hough^{a,*}, John Greenman^b and Timothy A. Paget^a
Departments of ^aBiological Sciences and ^bSurgery,
University of Hull, Hull HU6 7RX, UK

1. Introduction

Giardia intestinalis is a protozoan parasite which infects the gastrointestinal tract of man and animals. It is endemic throughout the world and is transmitted via faecal contamination of drinking water and food. *Giardia intestinalis* has a relatively simple life cycle alternating between the trophozoite (proliferative form) and the cyst (resting form). The nature of symptoms associated with *Giardia* infections varies between individuals with many cases being asymptomatic, however in symptomatic cases diarrhoea, weight loss, and abdominal cramps are commonly reported [1].

Treatment of *Giardia* typically involves a number of drugs belonging to the 5' nitroimidazoles. Metronidazole (1- β -hydroxyethyl-2-methyl-5-nitroimidazole) is the most commonly used as it is generally well tolerated [2]. In most cases *Giardia* responds well to treatment, however in 1–4% of cases drug resistance is responsible for treatment failure.

Several mechanisms of drug resistance have been investigated in the parasitic protozoa, including drug inactivation via redox cycling and improved drug efflux. Here we describe the use of phage antibody technology to probe the surface of *Giardia* to identify changes between metronidazole resistant and sensitive trophozoites, and to identify molecules which may confer resistance. We have also used this technology to generate antibodies against *Giardia* cysts.

*Correspondence to: Miss Victoria Hough, University of Hull, Department of Biological Sciences, Hardy Building, Cottingham Road, Hull HU6 7RX, UK. Fax: +44 1482 466033; E-mail: V.C.Hough@medschool.hull.ac.uk.

2. Methods

2.1. Use of the bacteriophage antibody display library

A human synthetic scFv Library #1 (Nissim library) [3] was obtained from Dr. G. Winter (MRC Centre for protein engineering, Cambridge). This library has more than 10^8 specificities consisting of a single V λ 3 light chain gene segment paired with an array of in vitro rearranged V_H gene segments [3].

2.2. Selection on *Giardia* trophozoites

To isolate antibody fragments that were specific to metronidazole resistant *Giardia* trophozoites, panning was undertaken as shown in Fig. 1. The trophozoites used in the positive rounds of panning were JKH-1, a metronidazole resistant strain. A laboratory strain that had not been cultured in the presence of metronidazole was used for the negative round of panning. Prior to panning the trophozoites were fixed in methanol to prevent motility, and blocked in milk powder/BSA buffer to prevent non-specific binding of the bacteriophage.

2.3. Selection on *Giardia* cysts

BV-M and MR-4 *Giardia* cysts were used for positive selection and *Acanthamoeba* cysts were used for the subtractive panning round. Four rounds of selection were undertaken in total, after which phage were selected at random for further study.

2.4. Whole cell ELISA

Supernatant containing single phage clones chosen at random after the final positive selection was added to methanol fixed target trophozoites in conical bottomed 96 well plates. After washing, binding was assayed by the addition of HRP-conjugated anti-M13 (Pharmacia) and ABTS was used as substrate. Absorbance was measured at 405–690 nm after transfer to flat bottomed plates. The negative controls were an anti-NIP bacteriophage clone and no bacteriophage.




Fig. 1. Panning protocol for selection on *Giardia* Trophozoites. Initially 1×10^{13} bacteriophage were added to metronidazole resistant trophozoites, 2×10^9 bacteriophage were removed and amplified in *E.coli* TG1 (1). 6.2×10^{12} bacteriophage were then added to metronidazole sensitive trophozoites for a subtractive selection step (2), the unbound bacteriophage were immediately incubated with metronidazole resistant trophozoites (3). After elution and amplification in *E.coli* TG1 the bacteriophage were then used in 2 further rounds of positive selection (4).

2.5. Flow cytometry

Clones that bound strongly by ELISA were selected for further study using flow cytometry. Trophozoites were incubated with the test phage clone and detected using an anti-M13 monoclonal antibody (Amersham Pharmacia Biotech) followed by a FITC-conjugated anti-mouse polyclonal antibody. Cells were analysed using a FACSCalibur flow cytometer with CellQuest software.

3. Results

3.1. Selection on metronidazole resistant *Giardia* trophozoites

300 clones were analysed by ELISA. Sixteen clones that showed variable binding to JKH-1 were chosen.

Table 1
Binding of selected bacteriophage to *Giardia* trophozoites

Clone	BV-M	JKH-1	MR-4	NESS
A2	15.6 %	–	–	0
E1	14.0 %	–	–	0
F2	13.9 %	–	–	24.1 %
F7	33.1 %	15.1 %	–	23.1 %
G2	17.5 %	–	–	30.9 %
G3	14.0 %	–	–	34.3 %
G12	21.9 %	13.5 %	–	33.3 %
H8	15.9 %	13.1 %	–	32.2 %
AD5	16.0 %	16.3 %	–	29.0 %
AE2	37.5 %	13.5 %	–	24.2 %
AE3	31.5 %	–	–	30.5 %
BE3	16.7 %	–	–	31.4 %
BE5	19.8 %	18.4 %	–	34.2 %
BF4	15.0 %	18.5 %	–	29.2 %
BF12	22.5 %	14.0 %	–	33.6 %
BH11	25.5 %	–	–	38.2 %

Table 2
Binding of selected bacteriophage clones to *Giardia* cysts

Clone	<i>Giardia</i> cyst strains			
	BV-M	JKH-1	MR-4	NESS
A10	–	18.0%	36.9%	–
B11	–	–	–	–
D3	–	24.3%	14.5%	18.3%
D4	–	–	26.3%	35.3%
F1	–	–	17.8%	11.4%
F5	–	18.3%	19.2%	10.6%
H2	–	–	–	–
H3	–	–	29.0%	–

CDR3 insert size was determined by PCR using previously described primers [3]. Flow cytometry was performed on four strains of *Giardia*, percentage binding to each strain can be seen in Table 1.

3.2. Selection on *Giardia* cysts

200 clones were analysed by ELISA. 8 clones were selected for study by flow cytometry on the basis of strong binding to MR-4 or JKH1 cysts. The degree of binding to each of 4 laboratory derived cysts can be seen in Table 2. Fluorescent microscopy was used to confirm the flow cytometry results.

4. Conclusions

In this study we have shown that it is possible to generate antibody fragments which bind to *Giardia* trophozoites and cysts. The clones show variable levels of binding and cross reactivity to different strains. Clone H3 appears specific for cysts from the MR-4 strain

whereas all other clones showed cross-reactivity with two or three trophozoite or cyst strains, as appropriate.

In the future we aim to select clones which are specific to metronidazole resistant trophozoites after additional rounds of cell selection. The existing clones will be used to characterise surface molecules and to determine any role(s) in resistance. We also plan to investigate possible differences in the surface structure of animal and human trophozoites.

References

- [1] P.F.L. Boreham, Giardiasis and its control, *The Pharmaceutical Journal* **31** (1991), 271–274.
- [2] C.D. Freeman, N.E. Klutman and K.C. Lamp, Metronidazole a therapeutic review and update, *Drugs* **54**(5) (1997), 679–708.
- [3] A. Nissim, H.R. Hoogenboom and I.M. Tomlinson et al., Antibody fragments from a “single pot” phage display library as immunochemical reagents, *EMBO, J.* **13** (1994), 628–629.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

